Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.gblinfra.com | |
Market Cap | 889.77 Cr. | |
Enterprise Value(EV) | 863.23 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 6.88 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 19.84 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 26.19 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 49.09 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 2.78 | Calculated using Price: 136.50 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 6.52 Cr. | 65,184,421 Shares |
FaceValue | 1 | |
Company Profile | ||
The company is engaged in the manufacturing and exporting of drug intermediates, pharmaceutical intermediates, bulk drug intermediates, food preservatives, lubricants, API/bulk drug, etc. |
1 Day |
|
-1.19% |
1 Week |
|
-2.11% |
1 Month |
|
-4.26% |
3 Month |
|
-4.83% |
6 Month |
|
+0.77% |
1 Year |
|
+32.37% |
2 Year |
|
+142.48% |
5 Year |
|
+54.45% |
10 Year |
|
+1434.15% |
5 years | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 100.66 | 32.64 | 26.25 | 11.60 | 13.14 | |
Return on Capital Employed (%) | 55.10 | 24.06 | 22.37 | 24.08 | 16.45 | |
Return on Assets (%) | 33.81 | 12.77 | 12.91 | 6.75 | 8.43 |
Particulars | 6 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 81 | 112 | 146 | 232 | 281 | 306 | |
Non Curr. Liab. | 68 | 46 | 46 | 61 | 39 | 73 | |
Curr. Liab. | 90 | 93 | 79 | 80 | 73 | 88 | |
Minority Int. | 4 | 4 | 5 | ||||
Equity & Liab. | 239 | 251 | 271 | 378 | 398 | 472 | |
Non Curr. Assets | 170 | 183 | 187 | 260 | 283 | 338 | |
Curr. Assets | 68 | 68 | 83 | 118 | 115 | 134 | |
Misc. Exp. not W/O | |||||||
Total Assets | 239 | 251 | 271 | 378 | 398 | 472 |
Particulars | 6 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 169 | 212 | 247 | 270 | 358 | 385 | |
Other Income | 1 | 1 | 0 | 1 | 3 | 7 | |
Total Income | 170 | 213 | 247 | 272 | 361 | 392 | |
Total Expenditure | -117 | -156 | -184 | -191 | -296 | -312 | |
PBIDT | 53 | 57 | 64 | 81 | 64 | 80 | |
Interest | -11 | -10 | -9 | -7 | -4 | -4 | |
Depreciation | -12 | -12 | -13 | -15 | -15 | -15 | |
Taxation | -32 | -12 | -16 | ||||
Exceptional Items | 51 | -3 | -7 | -6 | -1 | 0 | |
PAT | 81 | 31 | 34 | 22 | 33 | 45 | |
Minority Interest | |||||||
Share Associate | |||||||
Other Related Items | |||||||
Consolidated Net Profit | 81 | 31 | 34 | 22 | 33 | 45 | |
Adjusted EPS | 16 | 6 | 7 | 4 | 5 | 7 |
Particulars | 5 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 39 | 60 | 27 | 57 | 86 | |
Cash Fr. Inv. | -19 | -27 | -13 | -40 | -59 | |
Cash Fr. Finan. | -21 | -30 | -14 | -9 | -25 | |
Net Change | -1 | 3 | 0 | 7 | 2 | |
Cash & Cash Eqvt | 0 | 3 | 3 | 10 | 12 |
Tue, 10 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 In compliance with Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulation 2018 we enclose herewith the confirmation certificate datedJanuary 06 2023 received from M/s Bigshare Services Pvt. Ltd. Registrar and Share Transfer Agent of the Company for the quarter ended on December 31 2022. |
Sat, 31 Dec 2022
Closure of Trading Window Notice is hereby given that in terms of the Companys Insider Trading Regulation Code and pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 as amended the trading window for the purpose of dealing in securities of the Company shall remain closed from January 01 2023 till 48 hours after the unaudited financial results of the Company for the quarter ending on December 31 2022 are approved by the Board of Directors and filed with stock exchanges.The date of the Board meeting to consider the unaudited financial results of the Company for the quarter ending on December 31 2022 will be intimated separately in due course.Accordingly all connected persons/Designated persons are advised not to trade in the securities of the Company during the aforesaid period. |
Fri, 30 Dec 2022
Announcement under Regulation 30 (LODR)-Conversion of Securities We hereby inform you about the Conversion of 28 25 000 warrants into equity shares out of total 60 00 000 warrants allotted to non-promoters through the Allotment Committee of the Board of Directors of the Company in its meeting held on 30th December 2022. |
Wed, 25 Jan 2023 |
|
|
|
|
|